Page last updated: 2024-08-21

quinazolines and rociletinib

quinazolines has been researched along with rociletinib in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gilligan, D; Pacey, S; Tan, CS	1
Chiba, M; Kobayashi, Y; Mitsudomi, T; Mizuuchi, H; Murakami, I; Nishio, K; Sakai, K; Sato, K; Sekido, Y; Sesumi, Y; Shimoji, M; Suda, K; Takemoto, T; Tomizawa, K	1
Ballard, P; Box, M; Cantarini, M; Cross, D; Grist, M; Hickey, M; Jänne, PA; Johnström, P; Jordan, A; Kim, DW; Malmquist, J; Pickup, K; Thress, KS; Varnäs, K; Yang, JC; Yang, Z; Yates, JW	1

Reviews

1 review(s) available for quinazolines and rociletinib

Article	Year
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. The Lancet. Oncology, 2015, Volume: 16, Issue:9 Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines	2015

Other Studies

2 other study(ies) available for quinazolines and rociletinib

Article	Year
Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer. Cancer science, 2016, Volume: 107, Issue:4 Topics: Acrylamides; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Oncogenes; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines	2016
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Oct-15, Volume: 22, Issue:20 Topics: Acrylamides; Afatinib; Aniline Compounds; Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain Neoplasms; Caco-2 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Dogs; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Madin Darby Canine Kidney Cells; Male; Mice; Mice, SCID; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Xenograft Model Antitumor Assays	2016

Article

Year

Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.

Cancer science, 2016, Volume: 107, Issue:4

Topics: Acrylamides; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Oncogenes; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines

2016

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Oct-15, Volume: 22, Issue:20

Topics: Acrylamides; Afatinib; Aniline Compounds; Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain Neoplasms; Caco-2 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Dogs; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Madin Darby Canine Kidney Cells; Male; Mice; Mice, SCID; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Xenograft Model Antitumor Assays

2016